{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:02:58Z","timestamp":1791576178758,"version":"4.3.4"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_184816"],"award-info":[{"award-number":["310030_184816"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012189","name":"\u041c\u0415\u0413\u0410\u0413\u0420\u0410\u041d\u0422\u042b","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Eosinophil infiltration is a common finding in a broad spectrum of skin diseases, despite the fact that the skin is devoid of eosinophils under physiologic conditions. Although cutaneous eosinophilia is reactive, cytokine-mediated in most cases, diseases with an intrinsic mutation-mediated clonal expansion of eosinophils can also manifest on the skin. As eosinophils are involved in host defense, regulate immune responses, generate pruritus, induce remodeling and fibrosis, and can cause tissue damage, they have the capacity to actively contribute to the pathogenesis of diseases. Recent research provided deeper insights in the mechanisms, e.g., bacterial and viral clearance, blister formation, recruitment of cytotoxic T cells, and generation of pruritus, by which eosinophils might come into action. This review aims at providing an overview on the clinical presentations of eosinophil-associated dermatoses and the current understanding of their pathogenic role in these diseases. Further, we discuss the effects of therapies targeting eosinophils.<\/jats:p>","DOI":"10.1007\/s00281-021-00868-7","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T08:10:09Z","timestamp":1623053409000},"page":"393-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Eosinophils in skin diseases"],"prefix":"10.1007","volume":"43","author":[{"given":"Susanne","family":"Radonjic-Hoesli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Charlotte","family":"Br\u00fcggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Feldmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-7736","authenticated-orcid":false,"given":"Hans-Uwe","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-9407","authenticated-orcid":false,"given":"Dagmar","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"868_CR1","first-page":"553","volume":"1","author":"P Ehrlich","year":"1880","unstructured":"Ehrlich P (1880) Methodologische Beitr\u00e4ge zur Physiologie und Pathologie der verschiedenen Formen der Leukocyten. Z Klin Med 1:553\u2013560","journal-title":"Z Klin Med"},{"key":"868_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000358735","volume":"100","author":"S Radonjic-H\u00f6sli","year":"2014","unstructured":"Radonjic-H\u00f6sli S, Simon HU (2014) Eosinophils. Chem Immunol Allergy 100:193\u2013204. https:\/\/doi.org\/10.1159\/000358735","journal-title":"Chem Immunol Allergy"},{"key":"868_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","volume":"130","author":"P Valent","year":"2012","unstructured":"Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130:607\u2013612.e9. https:\/\/doi.org\/10.1016\/j.jaci.2012.02.019","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/j.1398-9995.2011.02694.x","volume":"66","author":"N Roth","year":"2011","unstructured":"Roth N, St\u00e4dler S, Lemann M, H\u00f6sli S, Simon HU, Simon D (2011) Distinct eosinophil cytokine expression patterns in skin diseases\u2014the possible existence of functionally different eosinophil subpopulations. Allergy. 66:1477\u20131486. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02694.x","journal-title":"Allergy."},{"key":"868_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaci.2010.11.002","volume":"127","author":"D Simon","year":"2011","unstructured":"Simon D, Hoesli S, Roth N, Staedler S, Yousefi S, Simon HU (2011) Eosinophil extracellular DNA traps in skin diseases. J Allergy Clin Immunol 127:194\u2013199. https:\/\/doi.org\/10.1016\/j.jaci.2010.11.002","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.13131","volume":"72","author":"E de Graauw","year":"2017","unstructured":"de Graauw E, Sitaru C, Horn M, Borradori L, Yousefi S, Simon HU, Simon D (2017) Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy. 72:1105\u20131113. https:\/\/doi.org\/10.1111\/all.13131","journal-title":"Allergy."},{"key":"868_CR7","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaci.2003.08.028","volume":"112","author":"MD Davis","year":"2003","unstructured":"Davis MD, Plager DA, George TJ, Weiss EA, Gleich GJ, Leiferman KM (2003) Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol 112:988\u2013994. https:\/\/doi.org\/10.1016\/j.jaci.2003.08.028","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/j.1398-9995.2012.02868.x","volume":"67","author":"M Morshed","year":"2012","unstructured":"Morshed M, Yousefi S, St\u00f6ckle C, Simon HU, Simon D (2012) Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 67:1127\u20131137. https:\/\/doi.org\/10.1111\/j.1398-9995.2012.02868.x","journal-title":"Allergy."},{"key":"868_CR9","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/jid.2015.106","volume":"135","author":"N Kunsleben","year":"2015","unstructured":"Kunsleben N, R\u00fcdrich U, Gehring M, Novak N, Kapp A, Raap U (2015) IL-31 Induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol 135:1908\u20131911. https:\/\/doi.org\/10.1038\/jid.2015.106","journal-title":"J Invest Dermatol"},{"key":"868_CR10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","volume":"98","author":"U R\u00fcdrich","year":"2018","unstructured":"R\u00fcdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, Hartmann K, Meyer NH, Gibbs BF, Raap U (2018) Eosinophils are a major source of Interleukin-31 in bullous pemphigoid. Acta Derm Venereol 98:766\u2013771. https:\/\/doi.org\/10.2340\/00015555-2951","journal-title":"Acta Derm Venereol"},{"key":"868_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/eji.200323727","volume":"33","author":"HU Simon","year":"2003","unstructured":"Simon HU, Pl\u00f6tz S, Simon D, Seitzer U, Braathen LR, Menz G, Straumann A, Dummer R, Levi-Schaffer F (2003) Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol 33:834\u2013839. https:\/\/doi.org\/10.1002\/eji.200323727","journal-title":"Eur J Immunol"},{"issue":"4","key":"868_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213","volume":"95","author":"R von Wasielewski","year":"2000","unstructured":"von Wasielewski R, Seth S, Franklin J, Fischer R, H\u00fcbner K, Hansmann ML, Diehl V, Georgii A (2000 Feb 15) Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 95(4):1207\u20131213","journal-title":"Blood."},{"key":"868_CR13","doi-asserted-by":"publisher","first-page":"1727116","DOI":"10.1080\/2162402X.2020.1727116","volume":"9","author":"SCS Simon","year":"2020","unstructured":"Simon SCS, Hu X, Panten J, Grees M, Renders S, Thomas D, Weber R, Schulze TJ, Utikal J, Umansky V (2020) Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. Oncoimmunology. 9:1727116. https:\/\/doi.org\/10.1080\/2162402X.2020.1727116","journal-title":"Oncoimmunology."},{"key":"868_CR14","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1056\/NEJMoa031261","volume":"349","author":"SG Pl\u00f6tz","year":"2003","unstructured":"Pl\u00f6tz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2334\u20132339. https:\/\/doi.org\/10.1056\/NEJMoa031261","journal-title":"N Engl J Med"},{"key":"868_CR15","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD (2019) Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med 380:1336\u20131346. https:\/\/doi.org\/10.1056\/NEJMoa1812185","journal-title":"N Engl J Med"},{"key":"868_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2567.2012.03556.x","volume":"136","author":"AM Kvarnhammar","year":"2012","unstructured":"Kvarnhammar AM, Cardell LO (2012) Pattern-recognition receptors in human eosinophils. Immunology. 136:11\u201320. https:\/\/doi.org\/10.1111\/j.1365-2567.2012.03556.x","journal-title":"Immunology."},{"key":"868_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000504847","volume":"181","author":"HU Simon","year":"2020","unstructured":"Simon HU, Yousefi S, Germic N, Arnold IC, Haczku A, Karaulov AV, Simon D, Rosenberg HF (2020) The cellular functions of eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol 181:11\u201323. https:\/\/doi.org\/10.1159\/000504847","journal-title":"Int Arch Allergy Immunol"},{"key":"868_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.alit.2020.11.003","volume":"70","author":"L Gigon","year":"2021","unstructured":"Gigon L, Yousefi S, Karaulov A, Simon HU (2021) Mechanisms of toxicity mediated by neutrophil and eosinophil granule proteins. Allergol Int 70:30\u201338. https:\/\/doi.org\/10.1016\/j.alit.2020.11.003","journal-title":"Allergol Int"},{"key":"868_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1084\/jem.150.6.1456","volume":"122","author":"AE Butterworth","year":"1979","unstructured":"Butterworth AE, Wassom DL, Gleich GJ, Loegering DA, David JR (1979) Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol 122:221\u2013229. https:\/\/doi.org\/10.1084\/jem.150.6.1456","journal-title":"J Immunol"},{"key":"868_CR20","doi-asserted-by":"publisher","first-page":"3146e50","DOI":"10.1073\/pnas.83.10.3146","volume":"83","author":"GJ Gleich","year":"1986","unstructured":"Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ (1986) Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A 83:3146e50. https:\/\/doi.org\/10.1073\/pnas.83.10.3146","journal-title":"Proc Natl Acad Sci U S A"},{"key":"868_CR21","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.4049\/jimmunol.142.12.4428","volume":"142","author":"RI Lehrer","year":"1989","unstructured":"Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ (1989) Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142:4428\u20134434","journal-title":"J Immunol"},{"key":"868_CR22","doi-asserted-by":"publisher","first-page":"7876","DOI":"10.1074\/jbc.270.14.7876","volume":"270","author":"HF Rosenberg","year":"1995","unstructured":"Rosenberg HF (1995) Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. J Biol Chem 270:7876\u20137881. https:\/\/doi.org\/10.1074\/jbc.270.14.7876","journal-title":"J Biol Chem"},{"key":"868_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/138920108784567236","volume":"9","author":"HF Rosenberg","year":"2008","unstructured":"Rosenberg HF (2008) Eosinophil-derived neurotoxin \/ RNase 2: connecting the past, the present and the future. Curr Pharm Biotechnol 9:135\u2013140. https:\/\/doi.org\/10.2174\/138920108784567236","journal-title":"Curr Pharm Biotechnol"},{"key":"868_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nm.1855","volume":"14","author":"S Yousefi","year":"2008","unstructured":"Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, Schmid I, Straumann A, Reichenbach J, Gleich GJ, Simon HU (2008) Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 14:949\u2013953. https:\/\/doi.org\/10.1038\/nm.1855","journal-title":"Nat Med"},{"key":"868_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/cells10020306","volume":"10","author":"N Germic","year":"2021","unstructured":"Germic N, Fettrelet T, Stojkov D, Hosseini A, Horn MP, Karaulov A, Simon D, Yousefi S, Simon HU (2021) The release kinetics of eosinophil peroxidase and mitochondrial DNA is different in association with eosinophil extracellular trap formation. Cells. 10:306. https:\/\/doi.org\/10.3390\/cells10020306","journal-title":"Cells."},{"key":"868_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.01.026","volume":"57","author":"A Soragni","year":"2015","unstructured":"Soragni A, Yousefi S, Stoeckle C, Soriaga AB, Sawaya MR, Kozlowski E, Schmid I, Radonjic-Hoesli S, Boutet S, Williams GJ, Messerschmidt M, Seibert MM, Cascio D, Zatsepin NA, Burghammer M, Riekel C, Colletier JP, Riek R, Eisenberg DS, Simon HU (2015) Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell 57:1011\u20131021. https:\/\/doi.org\/10.1016\/j.molcel.2015.01.026","journal-title":"Mol Cell"},{"key":"868_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/JLB.3MR1217-476R","volume":"104","author":"RCN Melo","year":"2018","unstructured":"Melo RCN, Weller PF (2018) Contemporary understanding of the secretory granules in human eosinophils. J Leukoc Biol 104:85\u201393. https:\/\/doi.org\/10.1002\/JLB.3MR1217-476R","journal-title":"J Leukoc Biol"},{"issue":"338","key":"868_CR28","doi-asserted-by":"publisher","first-page":"pe26","DOI":"10.1126\/stke.3382006pe26","volume":"2006","author":"R Moqbel","year":"2006","unstructured":"Moqbel R, Coughlin JJ (2006 Jun 6) Differential secretion of cytokines. Sci STKE 2006(338):pe26. https:\/\/doi.org\/10.1126\/stke.3382006pe26","journal-title":"Sci STKE"},{"key":"868_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2014.00496","volume":"5","author":"LA Spencer","year":"2014","unstructured":"Spencer LA, Bonjour K, Melo RC, Weller PF (2014) Eosinophil secretion of granule-derived cytokines. Front Immunol 5:496. https:\/\/doi.org\/10.3389\/fimmu.2014.00496","journal-title":"Front Immunol"},{"key":"868_CR30","doi-asserted-by":"publisher","first-page":"18478","DOI":"10.1073\/pnas.0804547105","volume":"105","author":"JS Neves","year":"2008","unstructured":"Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, Weller PF (2008) Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci U S A 105:18478\u201318483. https:\/\/doi.org\/10.1073\/pnas.0804547105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"868_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaci.2009.11.029","volume":"125","author":"JS Neves","year":"2010","unstructured":"Neves JS, Radke AL, Weller PF (2010) Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol 125:477\u2013482. https:\/\/doi.org\/10.1016\/j.jaci.2009.11.029","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR32","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jaci.2017.01.044","volume":"140","author":"S Radonjic-Hoesli","year":"2017","unstructured":"Radonjic-Hoesli S, Wang X, de Graauw E, Stoeckle C, Styp-Rekowska B, Hlushchuk R, Simon D, Spaeth PJ, Yousefi S, Simon HU (2017) Adhesion-induced eosinophil cytolysis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway, which is counterregulated by autophagy. J Allergy Clin Immunol 140:1632\u20131642. https:\/\/doi.org\/10.1016\/j.jaci.2017.01.044","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fimmu.2016.00328","volume":"7","author":"S Yousefi","year":"2016","unstructured":"Yousefi S, Simon HU (2016) NETosis\u2014does it really represent nature's \"suicide bomber\"? Front Immunol 7:328. https:\/\/doi.org\/10.3389\/fimmu.2016.00328","journal-title":"Front Immunol"},{"key":"868_CR34","doi-asserted-by":"publisher","first-page":"736e9","DOI":"10.1016\/j.coi.2012.08.010","volume":"24","author":"S Yousefi","year":"2012","unstructured":"Yousefi S, Simon D, Simon HU (2012) Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol 24:736e9. https:\/\/doi.org\/10.1016\/j.coi.2012.08.010","journal-title":"Curr Opin Immunol"},{"key":"868_CR35","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.153.5.2278","volume":"153","author":"S Finotto","year":"1994","unstructured":"Finotto S, Ohno I, Marshall JS, Gauldie J, Denburg JA, Dolovich J, Clark DA, Jordana M (1994) TNF-alpha production by eosinophils in upper airways inflammation (nasal polyposis). J Immunol 153:2278\u20132289","journal-title":"J Immunol"},{"key":"868_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","volume":"59","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 59:21\u201330. https:\/\/doi.org\/10.1136\/gut.2009.178558","journal-title":"Gut."},{"key":"868_CR37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1172\/JCI17974","volume":"112","author":"P Flood-Page","year":"2003","unstructured":"Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB (2003) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029\u20131036. https:\/\/doi.org\/10.1172\/JCI17974","journal-title":"J Clin Invest"},{"key":"868_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1165\/ajrcmb.25.3.4437","volume":"25","author":"A Richter","year":"2001","unstructured":"Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, Dent G, Holgate ST, Davies DE (2001) The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 25:385\u2013391. https:\/\/doi.org\/10.1165\/ajrcmb.25.3.4437","journal-title":"Am J Respir Cell Mol Biol"},{"key":"868_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jaci.2005.08.057","volume":"117","author":"I Puxeddu","year":"2006","unstructured":"Puxeddu I, Bader R, Piliponsky AM, Reich R, Levi-Schaffer F, Berkman N (2006) The CC chemokine eotaxin\/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol 117:103\u2013110. https:\/\/doi.org\/10.1016\/j.jaci.2005.08.057","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"868_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1067\/mai.2001.118510","volume":"108","author":"T Zheng","year":"2001","unstructured":"Zheng T, Zhu Z, Wang J, Homer RJ, Elias JA (2001 Oct) IL-11: insights in asthma from overexpression transgenic modeling. J Allergy Clin Immunol 108(4):489\u2013496. https:\/\/doi.org\/10.1067\/mai.2001.118510","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaci.2003.10.050","volume":"113","author":"AD Klion","year":"2004","unstructured":"Klion AD, Nutman TB (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113:30\u201337. https:\/\/doi.org\/10.1016\/j.jaci.2003.10.050","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR42","doi-asserted-by":"publisher","first-page":"15442","DOI":"10.3390\/ijms160715442","volume":"16","author":"HF Rosenberg","year":"2015","unstructured":"Rosenberg HF (2015) Eosinophil-derived neurotoxin (EDN\/RNase 2) and the mouse eosinophil-associated RNases (mEars): expanding roles in promoting host defense. Int J Mol Sci 16:15442\u201315455. https:\/\/doi.org\/10.3390\/ijms160715442","journal-title":"Int J Mol Sci"},{"key":"868_CR43","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.4049\/jimmunol.1600787","volume":"198","author":"AE Samarasinghe","year":"2017","unstructured":"Samarasinghe AE, Melo RC, Duan S, LeMessurier KS, Liedmann S, Surman SL, Lee JJ, Hurwitz JL, Thomas PG, McCullers JA (2017) Eosinophils promote antiviral immunity in mice infected with influenza A virus. J Immunol 198:3214\u20133226. https:\/\/doi.org\/10.4049\/jimmunol.1600787","journal-title":"J Immunol"},{"key":"868_CR44","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.06.002","volume":"6","author":"KM Leiferman","year":"2018","unstructured":"Leiferman KM, Peters MS (2018) Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract 6:1462\u20131482.e6. https:\/\/doi.org\/10.1016\/j.jaip.2018.06.002","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"868_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12016-012-8326-y","volume":"45","author":"K Altman","year":"2013","unstructured":"Altman K, Chang C (2013 Aug) Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol 45(1):47\u201362. https:\/\/doi.org\/10.1007\/s12016-012-8326-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"868_CR46","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/exd.13782","volume":"27","author":"KT Amber","year":"2018","unstructured":"Amber KT, Chernyavsky A, Agnoletti AF, Cozzani E, Grando SA (2018) Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes. Exp Dermatol 27:1322\u20131327. https:\/\/doi.org\/10.1111\/exd.13782","journal-title":"Exp Dermatol"},{"key":"868_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, H\u00e4mmerling GJ (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 16:609\u2013617. https:\/\/doi.org\/10.1038\/ni.3159","journal-title":"Nat Immunol"},{"key":"868_CR48","doi-asserted-by":"publisher","first-page":"e1317420","DOI":"10.1080\/2162402X.2017.1317420","volume":"6","author":"V Lucarini","year":"2017","unstructured":"Lucarini V, Ziccheddu G, Macchia I, LaSorsa V, Peschiaroli F, Buccione C, Sistigu A, Sanchez M, Andreone S, D\u2019Urso MT et al (2017) IL-33 restricts tumor growth and inhibits pulmonary metastasis melanoma bearing mice through eosinophils. OncoImmunology 6:e1317420. https:\/\/doi.org\/10.1080\/2162402X.2017.1317420","journal-title":"OncoImmunology"},{"key":"868_CR49","doi-asserted-by":"publisher","first-page":"e20190706","DOI":"10.1084\/jem.20190706","volume":"217","author":"IC Arnold","year":"2020","unstructured":"Arnold IC, Artola-Boran M, Gurtner A, Bertram K, Bauer M, Frangez Z, Becher B, Kopf M, Yousefi S, Simon HU, Tzankov A, M\u00fcller A (2020) The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J Exp Med 217:e20190706. https:\/\/doi.org\/10.1084\/jem.20190706","journal-title":"J Exp Med"},{"key":"868_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.13683","volume":"173","author":"N Ortonne","year":"2015","unstructured":"Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, Delfau-Larue MH, Chosidow O, Wolkenstein P, Roujeau JC (2015) Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol 173:50\u201358. https:\/\/doi.org\/10.1111\/bjd.13683","journal-title":"Br J Dermatol"},{"key":"868_CR51","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/exd.14014","volume":"28","author":"C Nakashima","year":"2019","unstructured":"Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K (2019) Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol 28:1405\u20131411. https:\/\/doi.org\/10.1111\/exd.14014","journal-title":"Exp Dermatol"},{"key":"868_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","volume":"117","author":"E Sonkoly","year":"2006","unstructured":"Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117:411\u2013417. https:\/\/doi.org\/10.1016\/j.jaci.2005.10.033","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR53","doi-asserted-by":"publisher","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, Nanda S, Fayne RA, Paolini JF, Romanelli P, Yosipovitch G (2021 Jan 11) Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. https:\/\/doi.org\/10.1111\/exd.14279","DOI":"10.1111\/exd.14279"},{"key":"868_CR54","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjd.16498","volume":"179","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Zeidi M, Bonciani D, Pena SM, Tiao J, Sahu S, Werth VP (2018) Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol 179:669\u2013678. https:\/\/doi.org\/10.1111\/bjd.16498","journal-title":"Br J Dermatol"},{"key":"868_CR55","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1684\/ejd.2019.3560","volume":"29","author":"K Shimizu","year":"2019","unstructured":"Shimizu K, Andoh T, Makino T, Yoshihisa Y, Mizawa M, Shimizu T (2019) Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression. Eur J Dermatol 29:268\u2013273. https:\/\/doi.org\/10.1684\/ejd.2019.3560","journal-title":"Eur J Dermatol"},{"key":"868_CR56","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jaci.2007.02.010","volume":"119","author":"D Simon","year":"2007","unstructured":"Simon D, Simon HU (2007) Eosinophilic disorders. J Allergy Clin Immunol 119:1291\u20131300. https:\/\/doi.org\/10.1016\/j.jaci.2007.02.010","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2019.01.002","volume":"46","author":"D Simon","year":"2019","unstructured":"Simon D, Simon HU (2019) Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol 46:29\u201333. https:\/\/doi.org\/10.1016\/j.coph.2019.01.002","journal-title":"Curr Opin Pharmacol"},{"key":"868_CR58","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","volume":"5","author":"FL Kuang","year":"2017","unstructured":"Kuang FL, Klion AD (2017) Biologic agents for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol Pract 5:1502\u20131509. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.001","journal-title":"J Allergy Clin Immunol Pract"},{"key":"868_CR59","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1146\/annurev-pharmtox-010814-124407","volume":"55","author":"S Radonjic-Hoesli","year":"2015","unstructured":"Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon HU (2015) Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol 55:633\u2013656. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124407","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"868_CR60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000497383","volume":"178","author":"D Simon","year":"2019","unstructured":"Simon D, Wollenberg A, Renz H, Simon HU (2019) Atopic dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019. Int Arch Allergy Immunol 178:207\u2013218. https:\/\/doi.org\/10.1159\/000497383","journal-title":"Int Arch Allergy Immunol"},{"key":"868_CR61","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1046\/j.1365-2133.2001.04456.x","volume":"145","author":"P Kiehl","year":"2001","unstructured":"Kiehl P, Falkenberg K, Vogelbruch M, Kapp A (2001) Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 145:720\u2013729. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04456.x","journal-title":"Br J Dermatol"},{"key":"868_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2222.1993.tb00310.x","volume":"23","author":"C Walker","year":"1993","unstructured":"Walker C, K\u00e4gi MK, Ingold P, Braun P, Blaser K, Bruijnzeel-Koomen CA, W\u00fcthrich B (1993) Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity. Clin Exp Allergy 23:145\u2013153. https:\/\/doi.org\/10.1111\/j.1365-2222.1993.tb00310.x","journal-title":"Clin Exp Allergy"},{"key":"868_CR63","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0091-6749(97)70031-9","volume":"99","author":"JF Cheng","year":"1997","unstructured":"Cheng JF, Ott NL, Peterson EA, George TJ, Hukee MJ, Gleich GJ, Leiferman KM (1997) Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 99:683\u2013692. https:\/\/doi.org\/10.1016\/s0091-6749(97)70031-9","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1056\/NEJM198508013130502","volume":"313","author":"KM Leiferman","year":"1985","unstructured":"Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 313:282\u2013285. https:\/\/doi.org\/10.1056\/NEJM198508013130502","journal-title":"N Engl J Med"},{"key":"868_CR65","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H, Stewart J, Kabashima K, XCIMA Study Group (2017) Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:826\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa1606490","journal-title":"N Engl J Med"},{"issue":"5","key":"868_CR66","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","volume":"60","author":"JM Oldhoff","year":"2005","unstructured":"Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Pl\u00f6tz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS (2005) Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 60(5):693\u2013696. https:\/\/doi.org\/10.1111\/j.1398-9995.2005.00791.x","journal-title":"Allergy."},{"key":"868_CR67","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/all.14050","volume":"75","author":"EG Kang","year":"2020","unstructured":"Kang EG, Narayana PK, Pouliquen IJ, Lopez MC, Ferreira-Cornwell MC, Getsy JA (2020) Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy 75:950\u2013953. https:\/\/doi.org\/10.1111\/all.14050","journal-title":"Allergy"},{"key":"868_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11882-017-0752-8","volume":"17","author":"PR Esser","year":"2017","unstructured":"Esser PR, Martin SF (2017) Pathomechanisms of contact sensitization. Curr Allergy Asthma Rep 17:83. https:\/\/doi.org\/10.1007\/s11882-017-0752-8","journal-title":"Curr Allergy Asthma Rep"},{"key":"868_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/all.12351","volume":"69","author":"D Simon","year":"2014","unstructured":"Simon D, Aeberhard C, Erdemoglu Y, Simon HU (2014) Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy. 69:125\u2013131. https:\/\/doi.org\/10.1111\/all.12351","journal-title":"Allergy."},{"key":"868_CR70","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/QCO.0b013e32835eb8a6","volume":"26","author":"SF Walton","year":"2013","unstructured":"Walton SF, Oprescu FI (2013) Immunology of scabies and translational outcomes: identifying the missing links. Curr Opin Infect Dis 26:116\u2013122. https:\/\/doi.org\/10.1097\/QCO.0b013e32835eb8a6","journal-title":"Curr Opin Infect Dis"},{"key":"868_CR71","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/00000372-199312000-00015","volume":"15","author":"S Said","year":"1993","unstructured":"Said S, Jay S, Kang J, Liem WH, Jensen JL, Jeffes EW 3rd. (1993) Localized bullous scabies. Uncommon presentation of scabies. Am J Dermatopathol 15:590\u2013593. https:\/\/doi.org\/10.1097\/00000372-199312000-00015","journal-title":"Am J Dermatopathol"},{"key":"868_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jaad.2004.03.003","volume":"52","author":"MA Ionescu","year":"2005","unstructured":"Ionescu MA, Rivet J, Daneshpouy M, Briere J, Morel P, Janin A (2005) In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 52:32\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2004.03.003","journal-title":"J Am Acad Dermatol"},{"key":"868_CR73","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.24233","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox RA (2016) Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:151\u2013165. https:\/\/doi.org\/10.1002\/ajh.24233","journal-title":"Am J Hematol"},{"key":"868_CR74","doi-asserted-by":"publisher","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 70:205.e1\u2013205.16. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.049","journal-title":"J Am Acad Dermatol"},{"key":"868_CR75","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/jid.2010.128","volume":"130","author":"T Miyagaki","year":"2010","unstructured":"Miyagaki T, Sugaya M, Fujita H, Ohmatsu H, Kakinuma T, Kadono T, Tamaki K, Sato S (2010) Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 130:2304\u20132311. https:\/\/doi.org\/10.1038\/jid.2010.128","journal-title":"J Invest Dermatol"},{"key":"868_CR76","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archderm.140.9.1057","volume":"140","author":"E Tancr\u00e8de-Bohin","year":"2004","unstructured":"Tancr\u00e8de-Bohin E, Ionescu MA, de La Salmoni\u00e8re P, Dupuy A, Rivet J, Rybojad M, Dubertret L, Bachelez H, Lebb\u00e9 C, Morel P (2004) Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 140:1057\u20131061. https:\/\/doi.org\/10.1001\/archderm.140.9.1057","journal-title":"Arch Dermatol"},{"key":"868_CR77","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","volume":"124","author":"PU Ogbogu","year":"2009","unstructured":"Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD (2009) Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124:1319\u201325.e3. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.022","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR78","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","volume":"341","author":"HU Simon","year":"1999","unstructured":"Simon HU, Pl\u00f6tz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:1112\u20131120. https:\/\/doi.org\/10.1056\/NEJM199910073411503","journal-title":"N Engl J Med"},{"key":"868_CR79","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000053723","volume":"124","author":"HU Simon","year":"2001","unstructured":"Simon HU, Pl\u00f6tz SG, Simon D, Dummer R, Blaser K (2001) Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol 124:242\u2013245. https:\/\/doi.org\/10.1159\/000053723","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"868_CR80","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaad.2017.05.060","volume":"78","author":"J Krooks","year":"2018","unstructured":"Krooks J, Minkov M, Weatherall AG (2018) Langerhans cell histiocytosis in children: Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol 78(6):1047\u20131056. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.060","journal-title":"J Am Acad Dermatol"},{"key":"868_CR81","first-page":"4195","volume":"94","author":"RM Egeler","year":"1999","unstructured":"Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E (1999) Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 94:4195\u20134201","journal-title":"Blood."},{"key":"868_CR82","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.0105-2896.2009.00883.x","volume":"234","author":"RM Egeler","year":"2010","unstructured":"Egeler RM, van Halteren AG, Hogendoorn PC, Laman JD, Leenen PJ (2010) Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev 234:213\u2013232. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00883.x","journal-title":"Immunol Rev"},{"key":"868_CR83","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","volume":"139","author":"WJ Pichler","year":"2003","unstructured":"Pichler WJ (2003) Delayed drug hypersensitivity reactions. Ann Intern Med 139:683\u2013693. https:\/\/doi.org\/10.7326\/0003-4819-139-8-200310210-00012","journal-title":"Ann Intern Med"},{"key":"868_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13601-015-0073-8","volume":"5","author":"R Schrijvers","year":"2015","unstructured":"Schrijvers R, Gilissen L, Chiriac AM, Demoly P (2015) Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy 5:31. https:\/\/doi.org\/10.1186\/s13601-015-0073-8","journal-title":"Clin Transl Allergy"},{"key":"868_CR85","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/jdv.16339","volume":"34","author":"EC Kuijper","year":"2020","unstructured":"Kuijper EC, French LE, Tensen CP, Vermeer MH, Bouwes Bavinck JN (2020) Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). J Eur Acad Dermatol Venereol 34:1957\u20131971. https:\/\/doi.org\/10.1111\/jdv.16339","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"868_CR86","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","volume":"68","author":"T Shiohara","year":"2019","unstructured":"Shiohara T, Mizukawa Y (2019) Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int 68:301\u2013308. https:\/\/doi.org\/10.1016\/j.alit.2019.03.006","journal-title":"Allergol Int"},{"key":"868_CR87","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC, RegiSCAR study group (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 169:1071\u20131080. https:\/\/doi.org\/10.1111\/bjd.12501","journal-title":"Br J Dermatol"},{"key":"868_CR88","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","volume":"156","author":"T Shiohara","year":"2007","unstructured":"Shiohara T, Iijima M, Ikezawa Z, Hashimoto K (2007) The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 156:1083\u20131084. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07807.x","journal-title":"Br J Dermatol"},{"key":"868_CR89","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bjd.12081","volume":"168","author":"S Walsh","year":"2013","unstructured":"Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, Creamer D (2013) Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 168:391\u2013401. https:\/\/doi.org\/10.1111\/bjd.12081","journal-title":"Br J Dermatol"},{"key":"868_CR90","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","volume":"156","author":"SH Kardaun","year":"2007","unstructured":"Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156:609\u2013611. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07704.x","journal-title":"Br J Dermatol"},{"key":"868_CR91","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaad.2009.08.050","volume":"63","author":"CC Ang","year":"2010","unstructured":"Ang CC, Wang YS, Yoosuff EL, Tay YK (2010) Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 63:219\u2013227. https:\/\/doi.org\/10.1016\/j.jaad.2009.08.050","journal-title":"J Am Acad Dermatol"},{"key":"868_CR92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fmed.2017.00179","volume":"4","author":"P Musette","year":"2017","unstructured":"Musette P, Janela B (2017) New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med (Lausanne) 4:179. https:\/\/doi.org\/10.3389\/fmed.2017.00179","journal-title":"Front Med (Lausanne)"},{"key":"868_CR93","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.12783","volume":"170","author":"MH Chi","year":"2014","unstructured":"Chi MH, Hui RC, Yang CH, Lin JY, Lin YT, Ho HC, Chung WH, Kuo TT (2014) Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS). Br J Dermatol 170:866\u2013873. https:\/\/doi.org\/10.1111\/bjd.12783","journal-title":"Br J Dermatol"},{"key":"868_CR94","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1046\/j.1365-2133.1998.02559.x","volume":"139","author":"G Choquet-Kastylevsky","year":"1998","unstructured":"Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC (1998) Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 139:1026\u20131032. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02559.x","journal-title":"Br J Dermatol"},{"key":"868_CR95","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","volume":"6","author":"N Ange","year":"2018","unstructured":"Ange N, Alley S, Fernando SL, Coyle L, Yun J (2018) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. J Allergy Clin Immunol Pract 6:1059\u20131060. https:\/\/doi.org\/10.1016\/j.jaip.2017.10.020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"868_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231355","volume":"12","author":"OS Thein","year":"2019","unstructured":"Thein OS, Sutton B, Thickett DR, Parekh D (2019) Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS. BMJ Case Rep 12:e231355. https:\/\/doi.org\/10.1136\/bcr-2019-231355","journal-title":"BMJ Case Rep"},{"key":"868_CR97","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jaip.2020.09.039","volume":"9","author":"P Schmid-Grendelmeier","year":"2021","unstructured":"Schmid-Grendelmeier P, Steiger P, Naegeli MC, Kolm I, Lang CCV, Maverakis E, Br\u00fcggen MC (2021) Benralizumab for severe DRESS in two COVID-19 patients. J Allergy Clin Immunol Pract 9:481\u2013483.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.039","journal-title":"J Allergy Clin Immunol Pract"},{"key":"868_CR98","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000507218","volume":"181","author":"M Maurer","year":"2020","unstructured":"Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, Jakob T, Kapp A, Kolkhir P, Larenas-Linnemann D, Park HS, Pejler G, S\u00e1nchez-Borges M, Sch\u00e4kel K, Simon D, Simon HU, Weller K, Zuberbier T, Metz M (2020) Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol 181:321\u2013333. https:\/\/doi.org\/10.1159\/000507218","journal-title":"Int Arch Allergy Immunol"},{"key":"868_CR99","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000155748","volume":"148","author":"M Cugno","year":"2009","unstructured":"Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R (2009) Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 148:170\u2013174. https:\/\/doi.org\/10.1159\/000155748","journal-title":"Int Arch Allergy Immunol"},{"key":"868_CR100","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/j.1398-9995.2009.02069.x","volume":"64","author":"A Tedeschi","year":"2009","unstructured":"Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M (2009) Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor in patients with chronic urticaria. Allergy. 64:1616\u20131622. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02069.x","journal-title":"Allergy."},{"key":"868_CR101","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jaci.2020.03.005","volume":"145","author":"S Altrichter","year":"2020","unstructured":"Altrichter S, Frischbutter S, Fok JS, Kolkhir P, Jiao Q, Skov PS, Metz M, Church MK, Maurer M (2020) The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol 145:1510\u20131516. https:\/\/doi.org\/10.1016\/j.jaci.2020.03.005","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR102","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","volume":"8","author":"P Kolkhir","year":"2020","unstructured":"Kolkhir P, Church MK, Altrichter S, Skov PS, Hawro T, Frischbutter S, Metz M, Maurer M (2020) Eosinopenia, in Chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract 8:318\u2013325.e5. https:\/\/doi.org\/10.1016\/j.jaip.2019.08.025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"868_CR103","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/ddg.13132_g","volume":"14","author":"AB Weins","year":"2016","unstructured":"Weins AB, Biedermann T, Weiss T, Weiss JM (2016) Wells-Syndrom. J Dtsch Dermatol Ges 14:989\u2013994. https:\/\/doi.org\/10.1111\/ddg.13132_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"868_CR104","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","volume":"126","author":"HU Simon","year":"2010","unstructured":"Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, Rosenwasser LJ, Roufosse F, Gleich GJ, Klion AD (2010) Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 126:45\u201349. https:\/\/doi.org\/10.1016\/j.jaci.2010.03.042","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"868_CR105","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archderm.1997.03890380075011","volume":"133","author":"RM Tr\u00fceb","year":"1997","unstructured":"Tr\u00fceb RM, L\u00fcbbe J, Torricelli R, Panizzon RG, W\u00fcthrich B, Burg G (1997 Feb) Eosinophilic myositis with eosinophilic cellulitis like skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5. Arch Dermatol 133(2):203\u2013206","journal-title":"Arch Dermatol"},{"key":"868_CR106","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2133.1983.tb07074.x","volume":"109","author":"MS Peters","year":"1983","unstructured":"Peters MS, Schroeter AL, Gleich GJ (1983) Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. Br J Dermatol 109:141\u2013148. https:\/\/doi.org\/10.1111\/j.1365-2133.1983.tb07074.x","journal-title":"Br J Dermatol"},{"key":"868_CR107","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jdcr.2018.02.011","volume":"4","author":"S Herout","year":"2018","unstructured":"Herout S, Bauer WM, Schuster C, Stingl G (2018) Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab. JAAD Case Rep 4:548\u2013550. https:\/\/doi.org\/10.1016\/j.jdcr.2018.02.011","journal-title":"JAAD Case Rep"},{"key":"868_CR108","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJM198406213102501","volume":"310","author":"GJ Gleich","year":"1984","unstructured":"Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O'Connell EJ, Kohler PF (1984) Episodic angioedema associated with eosinophilia. N Engl J Med 310:1621\u20131626. https:\/\/doi.org\/10.1056\/NEJM198406213102501","journal-title":"N Engl J Med"},{"key":"868_CR109","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3324\/haematol.2013.091264","volume":"100","author":"P Khoury","year":"2015","unstructured":"Khoury P, Herold J, Alpaugh A, Dinerman E, Holland-Thomas N, Stoddard J, Gurprasad S, Maric I, Simakova O, Schwartz LB, Fong J, Lee CC, Xi L, Wang Z, Raffeld M, Klion AD (2015) Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica. 100:300\u2013307. https:\/\/doi.org\/10.3324\/haematol.2013.091264","journal-title":"Haematologica."},{"key":"868_CR110","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/pai.13173","volume":"31","author":"V Bertrand","year":"2020","unstructured":"Bertrand V, Boccara O, Filhon B, Manca F, Lef\u00e8vre G, Groh M, Kahn JE (2020) Episodic angioedema with eosinophilia (Gleich syndrome) in children: a clinical review. Pediatr Allergy Immunol 31:297\u2013302. https:\/\/doi.org\/10.1111\/pai.13173","journal-title":"Pediatr Allergy Immunol"},{"key":"868_CR111","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3389\/fimmu.2018.01198","volume":"9","author":"A Matucci","year":"2018","unstructured":"Matucci A, Liotta F, Vivarelli E, Dies L, Annunziato F, Piccinni MP, Nencini F, Pratesi S, Maggi E, Vultaggio A (2018) Efficacy and safety of mepolizumab (anti-Interleukin-5) treatment in Gleich's Syndrome. Front Immunol 9:1198. https:\/\/doi.org\/10.3389\/fimmu.2018.01198","journal-title":"Front Immunol"},{"key":"868_CR112","doi-asserted-by":"publisher","first-page":"232470962098769","DOI":"10.1177\/2324709620987691","volume":"9","author":"JH Butterfield","year":"2021","unstructured":"Butterfield JH (2021) Successful long-term control of the syndrome of episodic angioedema with eosinophilia (Gleich Syndrome) with low-dose imatinib mesylate and prednisone. J Investig Med High Impact Case Rep 9:2324709620987691. https:\/\/doi.org\/10.1177\/2324709620987691","journal-title":"J Investig Med High Impact Case Rep"},{"key":"868_CR113","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/DAD.0000000000000067","volume":"36","author":"C Massone","year":"2014","unstructured":"Massone C, Cerroni L, Heidrun N, Brunasso AM, Nunzi E, Gulia A, Ambros-Rudolph CM (2014) Histopathological diagnosis of atopic eruption of pregnancy and polymorphic eruption of pregnancy: a study on 41 cases. Am J Dermatopathol 36:812\u2013821. https:\/\/doi.org\/10.1097\/DAD.0000000000000067","journal-title":"Am J Dermatopathol"},{"key":"868_CR114","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1046\/j.1365-2133.1999.02907.x","volume":"140","author":"MJ Rico","year":"1999","unstructured":"Rico MJ, Benning C, Weingart ES, Streilein RD, Hall RP 3rd. (1999) Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br J Dermatol 140:1079\u20131086. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02907.x","journal-title":"Br J Dermatol"},{"key":"868_CR115","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","volume":"143","author":"M Wakugawa","year":"2000","unstructured":"Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, Yamada H, Hirai K, Tamaki K, Furue M (2000) Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 143:112\u2013116. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03599.x","journal-title":"Br J Dermatol"},{"key":"868_CR116","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jdermsci.2017.07.019","volume":"87","author":"M Salz","year":"2017","unstructured":"Salz M, Haeberle S, Hoffmann J, Enk AH, Hadaschik EN (2017) Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE. J Dermatol Sci 87:309\u2013311. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.07.019","journal-title":"J Dermatol Sci"},{"issue":"3","key":"868_CR117","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","volume":"75","author":"D Simon","year":"2020","unstructured":"Simon D, Yousefi S, Cazzaniga S, B\u00fcrgler C, Radonjic S, Houriet C, Heidemeyer K, Kl\u00f6tgen HW, Kozlowski E, Borradori L, Simon HU (2020 Mar) Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 75(3):669\u2013672. https:\/\/doi.org\/10.1111\/all.13950","journal-title":"Allergy."},{"key":"868_CR118","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1468-3083.2010.03939.x","volume":"25","author":"I Zaraa","year":"2011","unstructured":"Zaraa I, Sellami A, Bouguerra C, Sellami MK, Chelly I, Zitouna M, Makni S, Hmida AB, Mokni M, Osman AB (2011) Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study. J Eur Acad Dermatol Venereol 25:1160\u20131167. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03939.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"868_CR119","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mjd.2002.125949","volume":"47","author":"AL Berlin","year":"2002","unstructured":"Berlin AL, Paller AS, Chan LS (2002) Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. J Am Acad Dermatol 47:169\u2013187. https:\/\/doi.org\/10.1067\/mjd.2002.125949","journal-title":"J Am Acad Dermatol"},{"key":"868_CR120","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1365-2249.2002.01755.x","volume":"127","author":"S Jean-Baptiste","year":"2002","unstructured":"Jean-Baptiste S, O'Toole EA, Chen M, Guitart J, Paller A, Chan LS (2002) Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. Clin Exp Immunol 127:470\u2013478. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01755.x","journal-title":"Clin Exp Immunol"},{"key":"868_CR121","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1165\/ajrcmb.21.3.f160","volume":"21","author":"ME Rothenberg","year":"1999","unstructured":"Rothenberg ME (1999) Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 21:291\u2013295. https:\/\/doi.org\/10.1165\/ajrcmb.21.3.f160","journal-title":"Am J Respir Cell Mol Biol"},{"key":"868_CR122","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaci.2011.11.034","volume":"129","author":"K Nakahigashi","year":"2012","unstructured":"Nakahigashi K, Doi H, Otsuka A, Hirabayashi T, Murakami M, Urade Y, Zouboulis CC, Tanizaki H, Egawa G, Miyachi Y, Kabashima K (2012) PGD2 induces eotaxin-3 via PPAR\u03b3 from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol 129:536\u2013543. https:\/\/doi.org\/10.1016\/j.jaci.2011.11.034","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR123","doi-asserted-by":"publisher","unstructured":"B\u00fcrgler C, Guillet C, Kolm I, Theiler M, Schmid-Grendelmeier P, Kroiss S, Weibel L (2021) Treatment of eosinophilic pustular folliculitis with benralizumab in a 13-year-old girl. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.17181","DOI":"10.1111\/jdv.17181"},{"key":"868_CR124","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","volume":"37","author":"N Weigelt","year":"2010","unstructured":"Weigelt N, Metze D, St\u00e4nder S (2010) Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 37:578\u2013586. https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01484.x","journal-title":"J Cutan Pathol"},{"issue":"7","key":"868_CR125","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/archderm.1993.01680280049009","volume":"129","author":"GL Perez","year":"1993","unstructured":"Perez GL, Peters MS, Reda AM, Butterfield JH, Peterson EA, Leiferman KM (1993 Jul) Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol 129(7):861\u2013865","journal-title":"Arch Dermatol"},{"key":"868_CR126","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ejp.767","volume":"20","author":"C Zeidler","year":"2016","unstructured":"Zeidler C, St\u00e4nder S (2016) The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration. Eur J Pain 20:37\u201340. https:\/\/doi.org\/10.1002\/ejp.767","journal-title":"Eur J Pain"},{"issue":"153","key":"868_CR127","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2133.2005.06752.x","volume":"2005","author":"A Gauger","year":"2005","unstructured":"Gauger A, Ronet C, Schnopp C, Abeck D, Hein R, K\u00f6hn F-M, Ring J, Ollert M, Mempel M (2005) High local interleukin 5 production in granuloma faciale (eosinophilicum): role of clonally expanded skin-specific CD4+ cells. Br J Dermatol 2005(153):454\u2013457. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06752.x","journal-title":"Br J Dermatol"},{"key":"868_CR128","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/PAS.0b013e318271efd0","volume":"37","author":"AM Cesinaro","year":"2013","unstructured":"Cesinaro AM, Lonardi S, Facchetti F (2013) Granuloma faciale: a cutaneous lesion sharing features with IgG4-associated sclerosing diseases. Am J Surg Pathol 37:66\u201373. https:\/\/doi.org\/10.1097\/PAS.0b013e318271efd0","journal-title":"Am J Surg Pathol"},{"key":"868_CR129","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ddg.12257_suppl","volume":"12","author":"K Buder","year":"2014","unstructured":"Buder K, Ruppert S, Trautmann A, Br\u00f6cker EB, Goebeler M, Kerstan A (2014) Angiolymphoid hyperplasia with eosinophilia and Kimura's disease\u2014a clinical and histopathological comparison. J Dtsch Dermatol Ges 12:224\u2013228. https:\/\/doi.org\/10.1111\/ddg.12257_suppl","journal-title":"J Dtsch Dermatol Ges"},{"key":"868_CR130","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1046\/j.1365-2222.2002.01552.x","volume":"32","author":"Y Kimura","year":"2002","unstructured":"Kimura Y, Pawankar R, Aoki M, Niimi Y, Kawana S (2002) Mast cells and T cells in Kimura's disease express increased levels of interleukin-4, interleukin-5, eotaxin and RANTES. Clin Exp Allergy 32:1787\u20131793. https:\/\/doi.org\/10.1046\/j.1365-2222.2002.01552.x","journal-title":"Clin Exp Allergy"},{"key":"868_CR131","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fmed.2017.00103","volume":"4","author":"MR Galdiero","year":"2017","unstructured":"Galdiero MR, Varricchi G, Seaf M, Marone G, Levi-Schaffer F, Marone G (2017) Bidirectional mast cell\u2013eosinophil interactions in inflammatory disorders and cancer. Front Med (Lausanne) 4:103. https:\/\/doi.org\/10.3389\/fmed.2017.00103","journal-title":"Front Med (Lausanne)"},{"key":"868_CR132","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0190-9622(98)70398-6","volume":"39","author":"MD Davis","year":"1998","unstructured":"Davis MD, Perniciaro C, Dahl PR, Randle HW, McEvoy MT, Leiferman KM (1998) Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients. J Am Acad Dermatol 39:27\u201335. https:\/\/doi.org\/10.1016\/s0190-9622(98)70398-6","journal-title":"J Am Acad Dermatol"},{"key":"868_CR133","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.annder.2010.02.001","volume":"137","author":"AF Chassine","year":"2010","unstructured":"Chassine AF, Dadban A, Charfi S, Chaby G, Royer B, Damaj G, Chatelain D, Lok C (2010) Eosinophilic dermatosis associated with hematological disorders: A clinical, histopathological and immunohistochemical study of six observations. Ann Dermatol Venereol 137:181\u2013188. https:\/\/doi.org\/10.1016\/j.annder.2010.02.001","journal-title":"Ann Dermatol Venereol"},{"key":"868_CR134","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/cup.13389","volume":"46","author":"F Meiss","year":"2019","unstructured":"Meiss F, Technau-Hafsi K, Kern JS, May AM (2019) Eosinophilic dermatosis of hematologic malignancy: correlation of molecular characteristics of skin lesions and extracutaneous manifestations of hematologic malignancy. J Cutan Pathol 46:175\u2013181. https:\/\/doi.org\/10.1111\/cup.13389","journal-title":"J Cutan Pathol"},{"key":"868_CR135","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jdv.15931","volume":"34","author":"SA Martinez-Cabriales","year":"2020","unstructured":"Martinez-Cabriales SA, Walsh S, Sade S, Shear NH (2020) Lymphomatoid papulosis: an update and review. J Eur Acad Dermatol Venereol 34:59\u201373. https:\/\/doi.org\/10.1111\/jdv.15931","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"868_CR136","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/10428199709059688","volume":"27","author":"K Kitano","year":"1997","unstructured":"Kitano K, Ichikawa N, Shimodaira S, Ito T, Ishida F, Kiyosawa K (1997) Eosinophilia associated with clonal T-cell proliferation. Leuk Lymphoma 27:335\u2013342. https:\/\/doi.org\/10.3109\/10428199709059688","journal-title":"Leuk Lymphoma"},{"key":"868_CR137","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.4049\/jimmunol.170.5.2435","volume":"170","author":"S Kusam","year":"2003","unstructured":"Kusam S, Toney LM, Sato H, Dent AL (2003) Inhibition of Th2 differentiation and GATA-3 expression by BCL-6. J Immunol 170:2435\u20132441. https:\/\/doi.org\/10.4049\/jimmunol.170.5.2435","journal-title":"J Immunol"},{"key":"868_CR138","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1182\/blood.V94.6.2065","volume":"94","author":"F Jundt","year":"1999","unstructured":"Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, M\u00fcller G, Foss HD, Royer HD, Stein H, D\u00f6rken B (1999) Hodgkin\/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood. 94:2065\u20132071","journal-title":"Blood."},{"key":"868_CR139","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V (2015) Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 21:5453\u20135459. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0676","journal-title":"Clin Cancer Res"},{"key":"868_CR140","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","volume":"10","author":"P Khoury","year":"2014","unstructured":"Khoury P, Grayson PC, Klion AD (2014) Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 10:474\u2013483. https:\/\/doi.org\/10.1038\/nrrheum.2014.98","journal-title":"Nat Rev Rheumatol"},{"key":"868_CR141","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, EGPA Mepolizumab Study Team (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921\u20131932. https:\/\/doi.org\/10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"868_CR142","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","volume":"9","author":"VP Guntur","year":"2021","unstructured":"Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, Kolakowski C, Strand MJ, Wechsler ME (2021) Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 9:1186\u20131193.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.054","journal-title":"J Allergy Clin Immunol Pract"},{"key":"868_CR143","doi-asserted-by":"publisher","unstructured":"Manka LA, Guntur VP, Denson JL, Dunn RM, Dollin YT, Strand MJ, Wechsler ME (2021) Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol S1081-1206(21)00097-1. https:\/\/doi.org\/10.1016\/j.anai.2021.01.035","DOI":"10.1016\/j.anai.2021.01.035"},{"key":"868_CR144","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.alit.2019.03.001","volume":"68","author":"H Ihn","year":"2019","unstructured":"Ihn H (2019) Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int 68:437\u2013439. https:\/\/doi.org\/10.1016\/j.alit.2019.03.001","journal-title":"Allergol Int"},{"key":"868_CR145","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","volume":"13","author":"I Pinal-Fernandez","year":"2014","unstructured":"Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM (2014) Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13:379\u2013382. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.019","journal-title":"Autoimmun Rev"},{"key":"868_CR146","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","volume":"53","author":"C Ferreli","year":"2017","unstructured":"Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L (2017) Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol 53:306\u2013336. https:\/\/doi.org\/10.1007\/s12016-017-8625-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"868_CR147","doi-asserted-by":"publisher","unstructured":"Kinoshita M, Ogawa Y, Onaka M, Shimada S, Kawamura T (2021) Mepolizumab-responsive Kimura disease. J Allergy Clin Immunol Pract S2213-2198(21)00292-0. https:\/\/doi.org\/10.1016\/j.jaip.2021.02.049","DOI":"10.1016\/j.jaip.2021.02.049"},{"key":"868_CR148","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ddg.13481_g","volume":"16","author":"M Magerl","year":"2018","unstructured":"Magerl M, Terhorst D, Metz M, Altrichter S, Zuberbier T, Maurer M, Bergmann KC (2018) Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges 16:476\u2013477. https:\/\/doi.org\/10.1111\/ddg.13481_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"868_CR149","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/jdv.14594","volume":"32","author":"M Maurer","year":"2018","unstructured":"Maurer M, Altrichter S, Metz M, Zuberbier T, Church MK, Bergmann KC (2018) Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol 32:e112\u2013e113. https:\/\/doi.org\/10.1111\/jdv.14594","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"868_CR150","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cells10010019","volume":"10","author":"BA Youngblood","year":"2020","unstructured":"Youngblood BA, Leung J, Falahati R, Williams J, Schanin J, Brock EC, Singh B, Chang AT, O'Sullivan JA, Schleimer RP, Tomasevic N, Bebbington CR, Bochner BS (2020) Discovery, function, and therapeutic targeting of Siglec-8. Cells. 10:19. https:\/\/doi.org\/10.3390\/cells10010019","journal-title":"Cells."},{"key":"868_CR151","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Su\u00e1rez-Fari\u00f1as M, Hager MD, Stahl N, Yancopoulos GD, Radin AR (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa1314768","journal-title":"N Engl J Med"},{"issue":"1","key":"868_CR152","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","volume":"83","author":"R Abdat","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, Gordon S, Ahmed R, Nichols A, Rothe M, Rosmarin D (2020 Jul) Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol 83(1):46\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.089","journal-title":"J Am Acad Dermatol"},{"key":"868_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13725","volume":"33","author":"A Goyal","year":"2020","unstructured":"Goyal A, Lofgreen S, Mariash E, Bershow A, Gaddis KJ (2020) Targeted inhibition of IL-4\/13 with dupilumab is an effective treatment for eosinophilic dermatosis of hematologic malignancy. Dermatol Ther 33:e13725. https:\/\/doi.org\/10.1111\/dth.13725","journal-title":"Dermatol Ther"},{"key":"868_CR154","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jdcr.2019.07.026","volume":"5","author":"A Jin","year":"2019","unstructured":"Jin A, Pousti BT, Savage KT, Mollanazar NK, Lee JB, Hsu S (2019) Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia. JAAD Case Rep 5:815\u2013817. https:\/\/doi.org\/10.1016\/j.jdcr.2019.07.026","journal-title":"JAAD Case Rep"},{"issue":"1","key":"868_CR155","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R (2019 Jan) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 143(1):135\u2013141. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"868_CR156","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Ta\u00efeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA (2018) Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78(5):863\u2013871.e11. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.017","journal-title":"J Am Acad Dermatol"},{"key":"868_CR157","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","volume":"137","author":"B King","year":"2017","unstructured":"King B, Lee AI, Choi J (2017) Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol 137:951\u2013995. https:\/\/doi.org\/10.1016\/j.jid.2016.10.044","journal-title":"J Invest Dermatol"},{"key":"868_CR158","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la Pe\u00f1a A, Nunes FP, Janes J, Gamalo M, Donley D, Paik J, DeLozier AM, Nickoloff BJ, Simpson EL (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913\u2013921.e9. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.018","journal-title":"J Am Acad Dermatol"},{"key":"868_CR159","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, Gu Y, Teixeira HD, Silverberg JI (2020) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 145:877\u2013884. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025","journal-title":"J Allergy Clin Immunol"},{"key":"868_CR160","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E (2019) Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 155:1371\u20131379. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855","journal-title":"JAMA Dermatol"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-021-00868-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-021-00868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T12:28:18Z","timestamp":1699100898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-021-00868-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1007\/s00281-021-00868-7","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Additional declarations for articles in life science journals that report the results of studies involving humans and\/or animals"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.U.S. is a consultant for GlaxoSmithKline. DS has been an investigator, advisory board member, or consultant for AbbVie, AstraZeneca, Galderma, LEO, Lilly, Pfizer, Roche Pharma, and Sanofi Genzyme. The other authors declare that they have no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}